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Abstract
Background To assess healthcare processes during treatment
of neovascular age-related macular degeneration (AMD) in
patients under real-life conditions and evaluate efficacy of
monthly visual acuity (VA) assessment in a pro re nata treat-
ment regime.
Methods Amulticentre, prospective, non-interventional study
based in Germany included neovascular AMD patients treated
with intravitreal ranibizumab. Patients completed a 3-month
loading phase with monthly intravitreal injections of 0.5 mg
ranibizumab, followed by a 12-month maintenance phase
during which investigators documented VA, additional injec-
tions, metamorphopsias, routine ophthalmological examina-
tions and adverse events at monthly follow-up visits. Efficacy
analysis included change from baseline in best-corrected VA
(BCVA) based on descriptive statistics.
Results A total of 2,232 patients were enrolled throughout
Germany and 1,729 patients (mean age 77.8 years, 63.2 %
women) comprised the efficacy population with a complete
set of data. In the clinical setting recorded in our study, only a
minority of patients underwent optical coherence tomography
during the maintenance phase (71 of 1,729 patients). Patients
received a mean total of 4.5 injections; three injections during
upload phase and 1.5 additional injections duringmaintenance
phase. Over half of the patients (51.4 %) did not receive
additional injections. Mean decimal BCVA increased during
the upload phase, (from LogMAR mean of 0.201 at baseline
to 0.219 at Month 4) but displayed a decline over time
(0.192 at Month 15).
Conclusion Ranibizumab treatment in a real-life setting dem-
onstrated efficacy in neovascular AMD patients, as shown by
initial gains in BCVA. However, maintenance and improve-
ment of these gains during the maintenance phase in a clinical
routine setting remained below those expected compared with
MARINA, ANCHOR and CATT trials, most likely due to a
low number of retreatments, and the high number of patients
with a poor response in regard to improvements of VA who
were not investigated in these studies.
Trial registration number This phase IV non-interventional
health services research study was conducted under the
Novartis internal registration code, CRFB002ADE10.
Keywords Age-related macular degeneration . Intravitreal
injections . Non-interventional study . Ranibizumab . Visual
acuity . Neovascular age-related macular degeneration
Introduction
Age-related macular degeneration (AMD) is a progressive
disease and the leading cause of irreversible vision loss among
people over 50 years of age in developed countries [1]. Today,
approximately 20 % of people 65 to 74 years of age have
findings of early macular degeneration, and at advanced age
(75 to 84 years) prevalence rates of blindness in the late stage
of AMD are up to 5 % [2].
In Germany, more than 370,000 people are currently diag-
nosed with neovascular AMD, with approximately 35,000
new cases occurring annually and calculations projecting a
dramatic increase of AMD-related blindness to occur by 2030
[3, 4]. AMD can be divided into two subtypes: dry and wet (or
neovascular) AMD. While the dry form is by far the most
frequent, 80% of the cases with severe vision loss in AMD are
due to wet AMD [5, 6]. This is characterised by abnormal
growth of new blood vessels. The age-related processes that
lead to the stimulation of pathologic neovascularisation are
not completely understood. However, vascular endothelial
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growth factor (VEGF) has been implicated as an important
factor in the process of neovascularisation [7]. Blockade of
VEGF has been shown to be effective in patients suffering
from neovascular AMD [8, 9].
There are currently three VEGF inhibitors approved for the
treatment of wet AMD in Germany: pegaptanib (Macugen®,
Pfizer, New York City, NY, US), ranibizumab (Lucentis®,
Novartis Pharmaceuticals, Basel, Switzerland), and recently
aflibercept (Eyelea®, BayerPharma AG, Berlin, Germany). A
fourth VEGF inhibitor, bevacizumab (Avastin®, Genentech,
Inc., California, US/Roche, Basel, Switzerland), is prescribed
‘off-label’ for the treatment of wet AMD [10].
The PIER study [11, 12] showed that a rigid three-monthly
regimen followed by ranibizumab injection every
three months led to inferior treatment outcomes compared
with the ANCHOR andMARINA studies using rigid monthly
treatment, and PrONTO studies which used a loading phase of
three consecutive monthly injections, followed by monthly
monitoring and retreatment in case of recurrence [8, 9, 13]. In
response to these findings, the German Ophthalmological
Society (DOG), the Retinological Society and the Association
of Ophthalmologists (BVA) recommended that patients in
Germany should be evaluated by their treating ophthalmolo-
gist at monthly intervals and retreatment should be performed
only in case of recurrence as utilised by the PrONTO studies
[10]. Criteria for retreatment were adopted from the PrONTO-
study [13]. Retreatment was only recommended in cases of
macular thickness increase greater than 100 μm upon optical
coherence tomography (OCT) examination, decrease in visual
acuity (VA) of five letters or more, new haemorrhage, or new
active classic choroidal neovascularisation (CNV) lesion.
The COMPASS study described here was based on these
initial European dosing recommendations with a loading
phase of three injections at a monthly interval followed by
retreatment in case of the following: visual loss of greater than
five Early Treatment Diabetic Retinopathy Study (ETDRS)
letters (or Snellen equivalent), an increase of retinal thickness
of more than 100 μm upon OCT assessment, a new haemor-
rhage, or new activity of lesion on fluorescence angiography
(FA) when observed during monthly monitoring. This patient-
outcome oriented variable-dosing (pro re nata [PRN]) regi-
men is applied for as long as the patient benefits [14]. The
European recommendations have since been updated and
currently state that ranibizumab should be administered at a
dose of 0.5 mg by intravitreal injection once per month until
maximum visual acuity (VA) is achieved and is stable for three
monthly assessments. This is followed by maintenance thera-
py, based on the results of individual patient monitoring with
retreatment only in case of recurrence [15].
While it is known that good results can be obtained fol-
lowing this PRN treatment regimen under conditions of a
controlled clinical study, little is known concerning the PRN
results in a clinical setting. The aim of this study was to assess
and evaluate the treatment of patients with wet AMD under
real-life conditions using the retreatment criteria as outlined
above, as well as to evaluate the efficacy of monthly VA




Patients included adult male and female patients (aged
≥18 years) with wet AMD prior to commencing treatment
with ranibizumab. Wet AMD was diagnosed according to
routine ophthalmologic diagnostic procedures (retinal exami-
nation by means of fundoscopy, FA, or OCT) by the investi-
gator or the referring doctor prior to start of the documenta-
tion. Classification of images was performed by the treating
physician. All treatment decisions were solely at the discretion
of the investigator and the patient, according to the usual
standard of care. The study sponsor did not attempt to influ-
ence the prescribing patterns of any individual investigator,
and the study medication was not provided by the study
sponsor.
Patient data were provided from 451 ophthalmic treatment
centers in Germany. The study was approved by the appropri-
ate ethics committee and conducted in accordance with the
recommendations of the German Federal Institute for Drugs
and Medical Devices on observational studies (§67 section 6
German Drug Law). Relevant national authorities were given
appropriate notification of the study.Written informed consent
to the collection and release of anonymous data (according to
the Declaration of Helsinki) was obtained from all patients
before determination of full eligibility.
Study design
COMPASS (Lucentis®-Versorgungsforschungsstudie zur wA-
MD - Stellenwert der zuweisenden Ophthalmologen im Vers-
orgungsnetzwerk wAMD) was a multicentre, prospective, ob-
servational (non-interventional), 15-month study composed of
a 3-month upload phase (Months 1–3) followed by a 12-
month maintenance phase (Month 4–15). Patients meeting
the eligibility criteria were enrolled into the three-month load-
ing phase, where three intravitreal injections of 0.5 mg
ranibizumab were administered monthly. In accordance with
the ranibizumab summary of product characteristics (SmPC)
valid at the time, patients were recommended follow-up visits
during the maintenance phase at monthly intervals after the
initial loading phase. Due to the nature of the study, visits were
not scheduled solely for the purpose of data collection.
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Efficacy outcomes
Patient VA, vision loss, metamorphopsias, and results of oph-
thalmologic routine examinations (if available) were recorded,
as well as the number of further injections administered during
the 12-month maintenance phase (Month 4–15) and the rea-
sons for not meeting the agreed visit date (if applicable). VA
was assessed bymeans of Snellen and ETDRS charts, and was
recorded decimally according to European standard EN ISO
8596 where possible. Documented VA noted as a Snellen
equivalent was converted into decimal notation. In addition,
finger-counting was rated as 0.01, hand movement as 0.005
and the perception of light as 0.001. Adverse events (AEs)
experienced by the patient were documented by the investi-
gator at each visit. At the final visit (Month 15), the investi-
gator and patient were requested to rate whether monthly
assessments were meaningful, and if they thought that the
recommendation of monthly follow-up visits could be easily
implemented from their individual perspectives.
Statistical analysis
Efficacy analysis was performed on patients over 50 years of
age with accurate and complete data (efficacy population),
using a last observation carried forward imputation. Patients
enrolled on the study that received ranibizumab, and for
whom correct documentation and baseline data were avail-
able, comprised the safety population from which AEs were
summarised using descriptive statistics. The primary endpoint
of this study was the mean change in BCVA from baseline.
Mean VA was calculated arithmetically and, to enhance the
comparability of changes, on a logarithmic basis (a difference
of 0.1 logMAR [log Minimum Angle Resolvable]-level is
equivalent to 1 EDTRS-line or 5 letters). The change in BCVA
over time was analysed using descriptive statistics (mean and
standard error of the mean). All analyses were exploratory, no




The first patient was screened in October 2007, and the last
patient completed the study in March 2011. A total of 2,232
patients were enrolled into the study from 451 centres
throughout Germany (Fig. 1). Of these 2,232 patients,
17 were excluded from analyses due to double docu-
mentation (n=9) or missing baseline data (n=8), thus,
the safety population was comprised of 2,215 patients.
A further 503 patients were excluded from the efficacy
population, most commonly due to: missing maintenance
phase follow-up data (n=238); incorrectly performed upload
phase (<3 injections or incorrect intervals between injections;
n=174); incorrectly recorded data (n=40); and no baseline VA
data gathered (n=22). The efficacy population, therefore, in-
cluded 1,729 patients.
Demographic and medical background data is displayed in
Table 1. As expected from an AMD patient population, the
mean age was 77.8 years, with half of the patients older than
78.8 years. There was an even distribution of disease between
left and right eyes, with a diagnosis of wet AMD in the right
eye of 865 patients and in the left eye of 841 patients. In
42.9 % (n=741) of cases, both eyes showed signs of AMD.
The form of CNV was occult in 41.3 % (n=714) of patients,
predominantly classic in 24.4 % (n=422), and minimally
classic in 7.8 % (n=134). No data on CNV type was available
for 26.5 % (n=458) of patients.
Fig. 1 Flow diagram of patient
participation. N number of
patients; VAvisual acuity
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Change in BCVA
Mean BCVA increased during the three-month upload phase,
from a LogMARmean of 0.201 at baseline to 0.219 at Month
4 (Fig. 2a). Improvement in BCVA from baseline was main-
tained up to the second follow-up visit during the maintenance
phase, at Month 5. Subsequent to this visit, mean BCVA
declined steadily over time during the maintenance phase,
from 0.233 at Month 5 to 0.192 at Month 15 (Fig. 2a). During
the study (Month 0–15), improvement in BCVA was
displayed by 40.5 % of patients, deterioration by 24.5 % of
patients and no change by 35.0 % of patients (Fig. 2b).
Self-assessment of VA
Changes in VA as measured by the investigator were in
accordance with patient self-assessment records (data not
shown). At the first follow-up visit during the maintenance
phase (Month 4), patients were asked if they had experienced
any vision loss. At each subsequent visit (Months 5–15),
patients were asked to classify their vision as ‘better’, ‘un-
changed’ or ‘worse’ as compared with the previous visit.
Following the three ranibizumab injections administered dur-
ing the upload phase, 29.8 % of patients evaluated their VA as
‘better’ at Month 5. Thereafter, the percentage of patients who
evaluated their VA as ‘better’ declined to 14.7 % at Month 15.
The percentage of patients who did not perceive any change in
VA during the maintenance phase increased from 57.8 % at
Table 1 Demographic data and baseline characteristics of the patients
(before upload-phase)
Variable (Na) Efficacy population
(N=1,729)
Age - years (N=1,718)
Mean (SD) 77.8
Range 50.1 – 97.1








Sex – n (%) (N=1692)
Male 599 (34.6)
Female 1.093 (63.2)
Previous treatment for AMD – n (%)b ≥5 %
None 1.171 (67.7)
Nutritional Supplements 362 (20.9)
Intravitreal injections 108 (6.2)
Risk factors - (%)b ≥5 %
Arterial hypertension 985 (57.0)
Diabetes mellitus 305 (17.6)
Dyslipidemia 199 (11.5)
Smoking 149 (8.6)
Myocardial infarction 91 (5.3)
Others 280 (16.2)
Most frequent diagnostic findings (ophthalmologic examinations) – n
(%)b,c ≥20 %
Intra-/subretinal fluid 1,176 (68.0)
New lesions 953 (55.1)
Intra-/subretinal bleeding 692 (40.0)
Best-corrected VA (N=1,729)
Arithmetic mean (SD) 0.277 (0.190)
Logarithmic mean 0.201
Intraocular pressure - mean (SD) (N=1,538) 15.22 (2.92)
AMD age-related macular degeneration; SD standard deviation
a Patients with available data; bmultiple naming possible; c residual pa-
tients were stated as “no” or “not specified”
Fig. 2 Change in BCVA during the study: a Mean BCVA during the
study (Efficacy population, LOCF) according logMAR values. b The
change in BCVA from baseline–Month 15 and Month 4–Month 15
according to the percentage of patients who improved (>0 lines),
remained unchanged, or declined (<0 lines), by logMAR BCVA. BCVA
best-corrected visual acuity; LOCF last observed carried forward
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Month 5 to 73.4 % at Month 15, compared with the percent-
age of patients who evaluated their vision as ‘worse’, which
remained similar throughout the study (12.3 % at Month 5
versus 13.8 % at Month 15). Patients were also asked to
evaluate metamorphopsia; the majority of patients classified
metamorphopsia as ‘unchanged’ throughout the study (55.8%
at Month 5; 70.1 % at Month 15).
Retreatment frequency during maintenance phase
Following the three initial monthly injections during the up-
load phase, 840 (48.6 %) patients received additional injec-
tions during the 12-month maintenance phase (average of 3.1
injections per patient, range 1 to 11 injections). In the efficacy
population (n=1,729), an average of 1.5 additional injections
were administered per patient during the maintenance phase,
resulting in an average of 4.5 ranibizumab injections received
per patient in total (three injections during upload phase plus
1.5 injections during maintenance phase). The percentage of
patients receiving additional injections increased steadily dur-
ing the maintenance phase fromMonth 4 (14.2 %) to Month 8
(19.1 %), then subsequently decreased each month until the
end of the study (13.6 % at Month 15).
Subgroup analysis
Subgroup analysis according to the number of retreatments
received during the maintenance phase demonstrated that all
patients who received additional injections during the main-
tenance phase presented a mean BCVA at Month 15 which
was below that achieved after the upload phase at Month 4
(Month 15: <4 injections, n=1,045; ≥4 injections, n=136; >6
injections, n=37, Fig. 3a). However, patients who received
fewer than four additional injections of ranibizumab during
the maintenance phase displayed less decline from baseline in
BCVA over the course of the study and levels did not fall
below baseline, compared with patients receiving more than
four injections (Fig. 3a). Analysis of the change in BCVA
from baseline to Month 15 according to the number of addi-
tional injections received by the patient during the mainte-
nance phase (0 injections, n=889; 1 injection, n=186; 2 in-
jections, n=195; 3 injections, n=240; 4 injections, n=85; 5
injections, n=68; >5 injections, n=66) shows that patients
who received one additional injection and those who did not
receive any additional injections both maintained similar
levels of BCVA during this time (both displayed a change
from baseline to Month 15 of -0.002 LogMAR; Fig. 3b). In
comparison, patients receiving two, three and five or more
additional injections experienced a loss in BCVA greater than
0.03 LogMAR during the maintenance phase (Fig. 3b). Only
those patients who received additional injections at four
follow-up visits during the maintenance phase showed an
improvement in BCVA (+0.016 versus baseline; Fig. 3b).
Change in BCVA during the study for patients receiving
additional injections was also analysed according to the fol-
lowing responder group definitions (Fig. 3c): ‘Gain and main-
tain’ (BCVA increases from baseline to Month 4 and then to
Month 15), ‘Gain but not maintain’ (BCVA increases from
baseline to Month 15, but with a decline fromMonth 4 to end
of study), and ‘No initial gain’ (BCVA declines from baseline
toMonth 4, but increases fromMonth 4 toMonth 15).Most of
the patients classified as ‘Gain and maintain’ received fewer
than four additional injections during the maintenance phase
Fig. 3 Change of VA from baseline to Month 15 according to the number
of additional injections: a, bMean change in BCVA from baseline-Month
15 according to the number of additional injections received during the
maintenance phase. cPercentage of patients receiving additional injections
according to criteria ‘Gain and maintain’ (BCVA at baseline < BCVA at
Month 4 < BCVA atMonth 15), ‘Gain but not maintain’ (BCVA at baseline
< BCVA atMonth 15 < BCVA atMonth 4), and ‘No initial gain’ (BCVA at
baseline > BCVA at Month 4 < BCVA at Month 15)
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(28.3 %), whereas the majority of patients classified as ‘Gain
but not maintain’ and ‘No initial gain’ received more than six
additional injections (15 % and 22.5 %, respectively)
(Fig. 3c). During the maintenance phase, patients showed
profit from therapy as documented by the increase of VA at
the visit following the injection.
Feasibility evaluation by investigators and patients
Investigators and patients were requested to rate whether
monthly assessment was meaningful and if the monitoring
recommendations provided in the SmPC could be easily
followed from the investigator’s and the patient’s perspectives
(Fig. 4). Of the 288 investigators and 1,369 patients who
responded, 58.0 % of the investigators and 70.3 % of the
patients found implementation of the recommended monthly
assessment into routine care to be fully feasible. Amongst
those investigators who found monthly assessment partly
feasible (36.5 %), the most common reasons given were due
to: cost, logistics and patient number (n=89); patient age and
multi-morbidity (n=18); and compliance problems (n=16).
For investigators who found monthly assessment not feasible
(5.6 %), reasons given were due to: cost, logistics and patient
number (n=9), and lack of reimbursement (n=9). The most
common reasons given by patients who found monthly as-
sessment partly feasible (26.9 %) were: too high burden
(n=82); transportation issues (n=76); and the high time
demands (n=58). Patients who found monthly assessment not
feasible (2.8 %) most commonly gave the reasons: too high
burden (n=15); transportation issues (n=5); and the high
expenditure of time (n=5).
Tolerability
The safety analysis was based on data from 2,215 patients
(Table 2). Investigators reported a total of 364 AEs in 123
patients during the entire observation period (AE incidence
rate 5.6 %). Of those, 255 AEs in 118 patients were serious
AEs (SAEs; incidence rate 5.3 %). For the majority of SAEs
(n=171; 67.1 %), any relationship to ranibizumab treatment
was not suspected. In 14.5% of cases (n=37), a relationship to
the treatment was suspected (unknown or no information for
47 SAEs). A total of 25 (1.1 %) patients discontinued the
study due to an AE.
Discussion
The present non-interventional study in 1,729 patients ob-
served the pharmacological treatment with ranibizumab of
wet AMD under routine clinical conditions. Patients received
a mean total of 4.5 injections during the 15-month study, three
during the upload phase and a further 1.5 injections on aver-
age during the maintenance phase. Although most patients
presented an improvement in or a stabilisation of VA, the
overall treatment efficacy remains below that expected from
previous controlled clinical trials.
In previous randomised trials the number of injections
received by patients was considerably higher: in the CATT
study, patients were treated with a mean of seven additional
injections during the first year [16]. In the ANCHOR study,
the mean number of ranibizumab injections administered
during two years of treatment was 21.3, and in the SUSTAIN
Fig. 4 Feasibility of the SmPC recommended monthly follow-up visits
in practice, as perceived by investigators and patients. SmPC summary of
product characteristics











Unknown/not reported 67 (26.3)
Most frequently (n ≥3) reported AE (SOC-term)
Eye disorders 18 (0.81)
Cardiac disorders 5 (0.23)
Injury, poisoning, complications 3 (0.14)
Most frequently (n ≥10) reported SAE (SOC-term)
Eye disorders 46 (2.08)
Surgical and medical procedures 23 (1.04)
Injury, poisoning, complications 17 (0.77)
General disorders and administration site conditions 16 (0.72)
Cardiac disorders 15 (0.68)
Neoplasms benign, malignant and unspecified 13 (0.59)
AEadverse event;MedDRAMedical Dictionary for Regulatory Activities;
SAE serious adverse event; SE side effect; SOC system-organ-class (ac-
cording to MedDRA); SSE serious side effect
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study patients received an additional 2.7 injections during the
8-month maintenance phase [9, 17].
Data from a phase IV uncontrolled, non-interventional trial
cannot be compared with the results of prospective controlled
phase II or III studies with accurate VA testing and motivated
patients. However, the striking difference in retreatment
shows that treatment in a clinical setting daily routine may
differ from that applied in controlled clinical trials. Real-world
data outside of a clinical trial setting suggest that a consider-
ably lower number of patients received the number of injec-
tions required to maintain or improve VA during the mainte-
nance phase using the previously specified retreatment
criteria. It could be argued that, although patients are being
examined on a regular basis, recurrence of the disease is
treated too late. This may be due to the fact that the criteria
for retreatment adopted from the PrONTO study are too broad
to effectively treat a recurrence under a routine clinical setting.
Several studies have shown that maintenance of VA is possi-
ble based upon a PRN regimen [13, 16–18]. In these studies, a
composite criterion was applied to assess the need for repeated
injections (functional vision loss and morphologic changes of
the macula and retina by OCT). Data from uncontrolled,
retrospective analyses show that a PRN regimen leading to
fewer than five injections in the first year are insufficient to
sustain VA improvements [19, 20]. However, this treatment
strategy was long regarded as sufficient and was based on a
mathematical drug and disease model (involving data from the
MARINA, ANCHOR and PIER studies) estimating 8.1
ranibizumab injections to be needed during the first year
[21]. In a real-life setting, it seems that these retreatment
criteria are not sufficient to adequately detect recurrence, as
during the maintenance phase, VA only partly recovers to the
same level achieved after upload therapy when measured by
ETDRS charts [22].
One reason for the comparably low overall development of
VA in this study might, therefore, be the fact that most of the
patients received clinical examination using decimal VA test-
ing. As retreatment is based upon a five-letter decrease of VA,
the standard VA testing using decimal VA charts might not be
sensitive enough to detect recurrence early enough [23]. Ad-
ditionally, clinical studies are usually based upon VA testing
using the ETDRS charts allowing a more sensitive assessment
of the development of VA. Usually, the change in VA in
clinical trials is reported in letters while the VA increase in
this study is primary recorded using the Snellen VA testing.
Another reason, which may contribute to the overall late
detection of recurrences, might be the fact that only a small
number of patients (n=71) received OCTexaminations during
maintenance phase assessments. It has been shown that
changes indicating a recurrence of wet AMD can be seen
upon close spectral domain (SD)-OCT examination before
deterioration of VA [13, 18, 21, 24] and recent studies such
as CATT are based upon OCT retreatment-criteria. Following
this, the ophthalmologic societies (DOG, BVA and the Ger-
man Retina Society [RG]) recently recommended implemen-
tation of morphologic criteria for re-injection (i.e., new haem-
orrhage, findings from morphologic criteria on OCT) which
are more sensitive to changes in the retina than functional
criteria [10]. However, at the time of the study, these
retreatment criteria were not present, thus, only a minority of
the patients were examined by OCT.
The authors consider it noteworthy that patients receiving
four injections of ranibizumab during maintenance displayed
the best visual outcomes. With a maximum of three additional
treatments during upload phase, these patients received up to
seven injections during a follow-up period of 15 months,
which is in accordance with the findings from the CATTstudy
(6.9 injections during a 12-month follow-up period) [16].
Interestingly, patients receiving more than five additional
injections did not present a better improvement of VA at
15 months, compared with those who received four additional
injections. Although one should be cautious in interpreting
data from an uncontrolled non-interventional study, this could
be due to the fact that these patients represent poor responders
to anti-VEGF treatment in regards to improvement of VA.
However, additional pathology, such as the presence of geo-
graphic atrophy or fibrosis, may also be responsible for lim-
iting the response to anti-VEGF treatment. It seems striking
that under real-life conditions, the proportion of poor re-
sponders seems higher than in clinical studies (e.g., SUSTAIN
study) [17]. However, to our understanding this can be
explained by strict inclusion criteria in these studies, which
were not present in our study. Additionally, in a routine
clinical setting there seems to be a high number of patients
with a lack of VA increase during upload therapy, and these
patients are less motivated to undergo the burden and the
logistic problems of an additional injection. Interestingly,
most patients and investigators found monthly assessment at
least partly feasible. Of note, the most prominent reasons for
refusal of monthly assessments were logistical problems and
high costs for all parties.
In the study described here, although initial gain of VA
after upload treatment could not be maintained during main-
tenance, VA at 12 months was stable compared with VA at
baseline. This stabilisation of VAwas also found in the overall
self-assessment of the patients: 73 % of patients stated that
they did not perceive any change in VA compared with
baseline.
Our results are in accordance with a recent study by
Heimes and colleagues reporting that the flexible, predomi-
nantly VA-driven ranibizumab retreatment regimen employed
in clinical practice in Germany, generally results in a loss of
BCVA during the 12 months of follow-up following initial
gains during upload phase [25].
Lastly, a lower than expected number of reported AEs was
observed during this study, with only a 5.6 % incidence rate.
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The majority of these AEs were classed as SAEs (255 of 364
AEs, 5.3 % incidence rate). In comparison, CATT reported an
SAE incidence rate of 31.7 % in the ranibizumab treatment
arm over two years [16]. These findings suggest that there is a
lack of reporting of both AEs and SAEs in a real-world
setting, as opposed to in a formal clinical trial.
Conclusion
This study showed that ranibizumab is effective in improving
VA in patients with wet AMD, as shown by the initial positive
treatment effects and short-term effects after retreatment. Al-
though most patients presented either with VA gain or
stabilisation during the 15 months follow-up, the overall treat-
ment success was lower than that observed in controlled clinical
trials. This indicates that the former retreatment criteria derived
from the PrONTO study are not sufficient to maintain VA
during maintenance phase of anti-VEGF treatment under real-
life settings. Considering the low retreatment rate when com-
pared with controlled clinical trials, it seems that in the clinical
routine setting recurrences are detected later than in clinical
trials. Thus, new retreatment criteria with regular assessments
of vision (i.e., VA assessments by ETDRS charts), or detection
of macular oedema increase by SD-OCT should be employed
in a clinical routine setting, as recommended by the DOG and
BVA and by the amended SmPC [26].
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